Douglas W. Blayney, MD, discusses phase II results of the combination of pegfilgrastim and plinabulin, as well as the importance of controlling chemotherapy-induced neutropenia for patients.
Use of immune checkpoint inhibitors correlates with high incidence of endocrinopathies, especially anti–CTLA-4 therapy.
The advent of immunotherapy options to treat patients with cancer has brought with it a new wave of immuno-related toxicities. One institution, Massachusetts General Hospital, has taken steps to establish an immunotherapy toxicity service care team, inspired by a 65-year-old patient with metastatic melanoma that had spread to his lungs and brain.
Cardiac resynchronization therapy improved heart function in patients who developed chemotherapy-induced cardiomyopathy.
The FDA has accepted a biologics license application to review eflapegrastim for the management of chemotherapy-induced neutropenia.
About 20% of fitness apps reviewed in a recent study were deemed appropriate for survivors of cancer, showing that they could be an effective tool in helping this population increase physical activity.
Updated venous thromboembolism (VTE) guidelines issued by the American Society of Clinical Oncology now include the use of direct oral anticoagulants for patients with cancer as a preventive measure against VTE recurrence.
The FDA has expanded the approval of aprepitant (Cinvanti) injectable emulsion for intravenous use to include the 130-mg single-dose regimen for patients receiving moderately epigenetic chemotherapy.
It is important for oncology surgeon trainees to learn to recognize when a palliative surgical procedure for an advanced malignancy might be appropriate, be familiar with the conduct of these operations, and understand the nuances of postoperative care and management of complications in this unique patient population.
The FDA has expanded the approval of aprepitant injectable emulsion to include a 2-minute intravenous use for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.